How Communicating Polygenic and Clinical Risk for Atherosclerotic Cardiovascular Disease Impacts Health Behavior: an Observational Follow-up Study

Abstract

Background: Prediction tools that combine polygenic risk scores with clinical factors provide a new opportunity for improved prediction and prevention of atherosclerotic cardiovascular disease, but the clinical utility of polygenic risk score has remained unclear. Methods: We collected a prospective cohort of 7342 individuals (64% women, mean age 56 years) and estimated their 10-year risk for atherosclerotic cardiovascular disease both by a traditional risk score and a composite score combining the effect of a polygenic risk score and clinical risk factors. We then tested how returning the personal risk information with an interactive web-tool impacted on the participants’ health behavior. Results: When reassessed after 1.5 years by a clinical visit and questionnaires, 20.8% of individuals at high (>10%) 10-year atherosclerotic cardiovascular disease risk had seen a doctor, 12.4% reported weight loss, 14.2% of smokers had quit smoking, and 15.4% had signed up for health coaching online. Altogether, 42.6% of persons at high risk had made one or more health behavioral changes versus 33.5% of persons at low/average risk such that higher baseline risk predicted a favorable change (OR [CI], 1.53 [1.37–1.72] for persons at high risk versus the rest, P <0.001), with both high clinical ( P <0.001) and genomic risk (OR [CI], 1.10 [1.03–1.17], P =0.003) contributing independently. Conclusions: Web-based communication of personal atherosclerotic cardiovascular disease risk-data including polygenic risk to middle-aged persons motivates positive changes in health behavior and the propensity to seek care. It supports integration of genomic information into clinical risk calculators as a feasible approach to enhance disease prevention.

Inframe insertion and splice site variants in MFGE8 associate with protection against coronary atherosclerosis

“…We tested the association of the two MFGE8 variants (rs534125149 and rs201988637) with quantitative measurements of cardiometabolic relevance or known risk factors for CVD in two sub-cohorts of FinnGen, the population-based national FINRISK study 65 ( n = 26,717) and GeneRISK 66 ( n = 7239). The associations were tested across 66 quantitative measurements of cardiometabolic relevance in FINRISK, and for 158 sub-lipid species in GeneRISK.…”

Lipidome- and genome-wide study to understand sex differences in circulatory lipids

“…The study included 7,292 participants, aged 45-66 years, from the ongoing prospective GeneRISK cohort recruited during 2015–2017 from Southern Finland. The recruitment process and sample collection procedures are described in detail in [42]. Briefly, participants were instructed to fast overnight for 10 hours before the blood samples were collected for plasma, serum and DNA extraction.…”

Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association

“…88,98 In a single-arm study, disclosure of a higher CAD PRS may influence favorable lifestyle behaviors. 99 Beyond lifestyle changes, it appears that PRS risk correlates with medication efficacy. Subgroup analyses in primary prevention statin trials indicated that those with high CAD PRS versus others derived greater relative and absolute clinical benefit from statins versus placebo (46% versus 26%; P heterogeneity =0.05) without differences in LDL-C reduction.…”